Enrollment is open for the Dual Epicardial and Endocardial Procedure (DEEP)Â clinical trial following U.S Food and Drug Administration Approval (FDA).Â
Food and Drug Administration gave 510(k) clearance for the HawkOne directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system provides physicians with an enhanced cutting mechanism to more effectively treat the widest variety of plaque in patients with peripheral arterial disease (PAD).
Shockwave Medical announced that the company will present clinical results from DISRUPT PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for the treatment of peripheral artery disease (PAD), at the Vascular Interventional Advances (VIVA) Annual Conference taking place Nov. 4-7 in Las Vegas.
Genetic predisposition to elevated low-density lipoprotein cholesterol (LDL-C) was associated with aortic valve calcium and narrowing of the aortic valve, findings that support a causal association between LDL-C and aortic valve disease, according to a study appearing in JAMA.
